An Open-Label Randomized Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma | NYU Langone Health

An Open-Label Randomized Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Cervical Cancer
Age: Between 18 years - 100 years
Gender: Female

Other Inclusion Criteria:

1. Patient must have recurrent, persistent, and/or metastatic cervical cancer, for which there is not a curative-intent option 2. Tumor progression or recurrence within 6 months of last dose of platinum therapy

You may not be eligible for this study if the following are true:

1. Patients with ongoing or recent (within 5 yrs) evidence of significant autoimmune disease, which requires treatment with systemic immunosuppressive agents 2. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway 3. Prior treatment with idelalisib 4. Patients with known history of brain metastasis(es) that may be considered active